A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study
Background: Recent studies have reported findings regarding the addition of pegylated interferon aligned -alpha (Peg- IFNα) to nucleos (t) analog ideas. This study was designed to compare the efficacy of Peg- IFNα therapy and tenofovir disoproxil fumarate (TDF) in combination with each treatment separately.
Methods: In this open-label, randomized clinical trial, treatment-naive hepatitis B e antigen (HBeAg) -negative patients were randomly assigned to three treatment groups: Group A: Peg- IFNα (180 mcg / week) with TDF (300 mg / day); Group B: TDF (300 mg / day); and Group C: Peg- IFNα (180 mcg / week). intervention runs 48 weeks and patients were followed every 12 weeks. Primary endpoint was the burden of HBV DNA <20 IU / mL.
Results: Group A, B and C, each consisting of 22, 23 and 22 patients, respectively. The number of patients with HBV DNA suppression in group A was significantly higher than in group B and C (P = 0.034). No significant differences were observed in the trend of normalization of serum ALT levels between the three groups (P = 0.082). At week 48, the combination therapy was significantly more effective in suppressing HBV DNA concentrations below detection levels of TDF monotherapy (OR = 2.1, 95% CI: 1.18 to 4.15; P = 0.034). In addition, the comparison between the monotherapy arm revealed that both interventions have the same effect on the overall outcome (OR = 1.24, 95% CI: 1.02 to 5.8; P = 0.062).
Conclusion: A Peg- IFNα and TDF combination therapy resulted in a good and safe virologic response in patients with HBeAg negative. Monotherapy with Peg-IFNα or TDF benefit was limited compared.
A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study
Double-blind, randomized trial to compare the efficacy of escitalopram compared to citalopram for depression induced interferon in patients with hepatitis C
Objective: The objective of this study was to compare two antidepressant drug citalopram and escitalopram on the basis of success in depressed patients of hepatitis C patients who received interferon.
Methods: In a double-blind randomized trial, patients with hepatitis C visit the National institute liver and gastro intestinal diseases (NILGID), Dow University Hospital, screened for depression before starting treatment with interferon. Institutional review board approval was obtained and references no.is mail: IRB-682 / DUHS / approval / 2016/169. Patients with a history of depression were excluded from the study. The patients who started therapy with interferon assessed for depression at baseline and then at each visit. Those who develop depression were randomly assigned to receive either citalopram or escitalopram. treatment groups was assessed by a scale of depression every time they visit the clinic. Two antidepressants compared to their success in an interval of 4 weeks, 8weeks and then 12 weeks.
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: Pre-made over-expression lentivirus for expressing human target: IFNAR2 (interferon (alpha, beta and omega) receptor 2), [alternative names: IFN-alpha-REC; IFN-R; IFNABR; IFNARB]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_207585.2. It also contains a RFP-Blasticidin dual selection marker.
Results: In the present study 80 patients were randomized to receive either citalopram or escitalopram. The research result was better in patients treated with escitalopram. Significant changes in depression scores from the beginning to the end of the study was greater in the escitalopram group is 10.41 compared with citalopram group is 14.17. Differences in depression scores were also calculated as 4.28 and.3.76 (p <0.001) for both drugs at week 8 and week 12 respectively, which were statistically significant. Difference in depression scores were also calculated for the sex of 0.576 (p = 0.497) and age of 0.950 (p = 0.265), were found to be significant, statistically.
Conclusion: The results show the superiority of escitalopram over citalopram, the drug is twice as potent as racemic mixtures. In addition the drug is well tolerated and showed a better effect. Escitalopram proven to be a safer alternative to citalopram.
